Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 102 Carcinoma, Intraductal, Noninfiltrating 12 Breast Carcinoma In Situ 10 Ovarian Neoplasms 6 Neoplasm Metastasis 6 Breast Neoplasms, Male 6 Neoplasms 5 Glioblastoma 5 Central Nervous System Neoplasms 5 Prostatic Neoplasms 4 Gliosarcoma 4 Inflammatory Breast Neoplasms 3 Glioma 3 Brain Neoplasms 3 Astrocytoma 3 Urinary Bladder Neoplasms 2 Pancreatic Neoplasms 2 Oligodendroglioma 2 Glioma, Subependymal 2 Fallopian Tube Neoplasms 2 Ependymoma 2 Breast Cancer Female 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thyroid Cancer, Papillary 1 Sarcoma 1 Risk Reduction Behavior 1

Interventions

lutetium Lu 177 dotatate 15 Everolimus 11 Nivolumab 10 pembrolizumab 9 Temozolomide 9 Capecitabine 7 cabozantinib 6 Sunitinib 6 lenvatinib 5 lanreotide 4 gallium Ga 68 dotatate 4 Ipilimumab 4 Etoposide 4 Carboplatin 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 telotristat ethyl 3 pazopanib 3 avelumab 3 Octreotide 3 Magnetic Resonance Spectroscopy 3 Injections 3 Cyclophosphamide 3 Cisplatin 3 Bevacizumab 3 surufatinib 2 sintilimab 2 fosbretabulin 2 fludarabine 2 Specimen Handling 2 Sorafenib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neuroendocrine Tumors × Tamoxifen × Clear all

NCT03870399 2024-05-06

HORMONET

AC Camargo Cancer Center

Phase 2 Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡